RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.
In this study, we determined the respective roles of RelA and RelB NF-κB subunits in Epstein-Barr virus (EBV)-transformed B cells. Using different EBV-immortalized B-cell models, we showed that only RelA activation increased both survival and cell growth. RelB activity was induced secondarily to RelA activation and repressed RelA DNA binding by trapping the p50 subunit. Reciprocally, RelA activation repressed RelB activity by increasing expression of its inhibitor p100. To search for such reciprocal inhibition at the transcriptional level, we studied gene expression profiles of our RelA and RelB regulatable cellular models. Ten RelA-induced genes and one RelB-regulated gene, ARNTL2, were repressed by RelB and RelA, respectively. Apart from this gene, RelB signature was included in that of RelA Functional groups of RelA-regulated genes were for control of energy metabolism, genetic instability, protection against apoptosis, cell cycle and immune response. Additional functions coregulated by RelA and/or RelB were autophagy and plasma cell differentiation. Altogether, these results demonstrate a cross-inhibition between RelA and RelB and suggest that, in fine, RelB was subordinated to RelA. In the view of future drug development, RelA appeared to be pivotal in both classical and alternative activation pathways, at least in EBV-transformed B cells.
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
A
A
Chanut
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
F
F
Duguet
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
A
A
Marfak
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
A
A
David
CHU Dupuytren, Laboratory of Pathology, Limoges, France.
B
B
Petit
CHU de Bordeaux, Laboratory of Pathology, Bordeaux, France.
M
M
Parrens
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
S
S
Durand-Panteix
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
M
M
Boulin-Deveza
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
N
N
Gachard
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
I
I
Youlyouz-Marfak
1] CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France [2] Department of Hematology, CHU Dupuytren, Limoges, France.
D
D
Bordessoule
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
J
0000000162232454
J
Feuillard
CNRS-UMR-7276, University of Limoges, and CHU Dupuytren, Laboratory of Hematology, Limoges, France.
N
N
Faumont
D002460:Cell Line; D002472:Cell Transformation, Viral; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000209:etiology*; D016328:NF-kappa B / Q000502:physiology; D051996:Transcription Factor RelA / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D051841:Transcription Factor RelB / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D059467:Transcriptome
D016328:NF-kappa B; C498143:RELA protein, human; C497593:RELB protein, human; D051996:Transcription Factor RelA; D051841:Transcription Factor RelB